NNP
ALXN

Nachman Norwood & Parrott’s Alexion Pharmaceuticals ALXN Stock Holding History

Nachman Norwood & Parrott’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$11K – 1166
2020
Q3 		$11K Buy
+100
New +$10.8K ﹤0.01% 746

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Nachman Norwood & Parrott's ALXN Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 100 shares — an estimated $11K sold.

Nachman Norwood & Parrott first reported a position in ALXN in Q3 2020 and held it in 1 quarter. The position peaked at $11K in Q3 2020. 824 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 100 Alexion Pharmaceuticals shares in Q4 2020, an estimated $11K.
  • Nachman Norwood & Parrott first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Alexion Pharmaceuticals position peaked at $11K in Q3 2020.
  • 824 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.